A systematic review of the effectiveness of adalimumab

1. Jobanputra P, Barton P, Bryan S, Burls A. The
effectiveness of infliximab and etanercept for the
treatment of rheumatoid arthritis: a systematic
review and economic evaluation. Health Technol
Assess 2002;6(21).
2. Barton P, Jobanputra P, Wilson J, Bryan S, Burls A.
The use of modelling to evaluate new drugs for
patients with a chronic condition: the case of
antibodies against tumour necrosis factor in
rheumatoid arthritis. Health Technol Assess 2004;
8(11).
3. Clark W, Jobanputra P, Barton P, Burls A. The
clinical and cost-effectiveness of anakinra for the
treatment of rheumatoid arthritis in adults: a
systematic review and economic analysis. Health
Technol Assess 2004;8(18).
4. Wiles NJ, Scott DGI, Barrett EM, Merry P, Arie E,
Gaffney K, et al. Benchmarking: the five year
outcome of rheumatoid arthritis assessed using a
pain score, the Health Assessment Questionnaire
and the Short Form-36 in a community and a
clinic based sample. Ann Rheum Dis 2001;
60:956–61.
5. Jacoby R, Jayson M, Cosh J. Onset, early stages,
and prognosis of rheumatoid arthritis: a clinical
study of 100 patients with 11-year follow-up. BMJ
1973;ii:96–100.
6. Arnett FC, Edworthy S, Bloch D. The American
Rheumatism Association 1987 revised criteria for
the classification of rheumatoid arthritis. Arthritis
Rheum 1988;31:315–24.
7. Wiles N, Symmons D, Harrison B, Barrett E,
Barrett J, Scott D. Estimating the incidence of
rheumatoid arthritis. Trying to hit a moving
target? Arthritis Rheum 1999;42:1339–46.
8. Ashcroft J. Arthritis: understanding people’s everyday
needs. London: Arthritis Care; 1997.
9. Ostergaard M, Hansen M, Stoltenberg M,
Jensen KE, Szkudlarek M, Pedersen-Zbinden B, et
al. New radiographic bone erosions in the wrists of
patients with rheumatoid arthritis are detectable
with magnetic resonance imaging a median of two
years later. Arthritis Rheum 2003;48:2128–31.
10. Goldbach-Mansky R, Woodburn J, Yao L,
Lipsky PE. Magnetic resonance imaging in the
evaluation of bone damage in rheumatoid
arthritis: a more precise image or just a more
expensive one? Arthritis Rheum 2003;48:585–9.
References
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
Health Technology Assessment 2006; Vol. 10: No. 42
11. Symmons D, Turner G, Webb R, Asten P, Barrett
E, Lunt M, et al. The prevalence of rheumatoid
arthritis in the United Kingdom: new estimates for
a new century. Rheumatology 2002;41:793–800.
12. National Statistics website. People and migration.
URL: http://www.statistics.gov.uk. Accessed
16 March 2005.
13. MacGregor A, Snieder H, Rigby A, Koskenvuo M,
Kapiro J, Aho K. Characterising the quantitative
genetic contribution to rheumatoid arthritis using
data from twins. Arthritis Rheum 2000;43:30–7.
14. Jones MA, Silman AJ, Whiting S, Barrett EM,
Symmons DP. Occurrence of rheumatoid arthritis
is not increased in the first degree of relatives of a
population based inception cohort of
inflammatory polyarthritis. Ann Rheum Dis 1996;
55:89–93.
15. Newton JL, Harvey SM, Wordsworth BP, Brown
MA. A review of the MHC genetics of rheumatoid
arthritis. Genes Immun 2004;5:151–7.
16. Edwards JCW, Cambridge G. Prospects for B-cell
targeted therapy in autoimmune disease.
Rheumatology 2005;44:151–6.
17. Moreland L. Inhibitor of tumor necrosis factor for
rheumatoid arthritis. J Rheumatol 1999;26(Suppl):
7–15.
18. Verhoeven A, Boers M, Tugwell P. Combination
therapy in rheumatoid arthritis: updated
systematic review. Br J Rheumatol 1998;37:612–19.
19. Kollias G, Douni E, Kassiotis G, Kontoyiannis D.
The function of tumour necrosis factor and
receptors in models of multi-organ inflammation,
rheumatoid arthritis, multiple sclerosis and
inflammatory bowel disease. Ann Rheum Dis 1999;
58(Suppl 1):32–9.
20. McDermott MF, Aksentijevich I, Galon J,
McDermott EM, Ogunkolade BW, Centola M, et al.
Germline mutations in the extracellular domains
of the 55 kDa TNF receptor, TNFR1, define a
family of dominant inherited autoinflammatory
disorders. Cell 1999;97:133–44.
21. Xanthoulea S, Pasparakis M, Kousteni S,
Brakebusch C, Wallach D, Bauer J, et al. Tumour
necrosis factor (TNF) receptor shedding controls
thresholds of innate immune activation that
balance opposing TNF functions in infectious and
inflammatory diseases. URL:
http://www.jem.org/cgi/doi/10.1084/jem.20040345.
Accessed 20 March 2005.
127